Connexios Life Sciences, a research and development company focused on developing novel therapeutics for metabolic disorders, today announced that preclinical data on CNX-011-67, a highly potent and selective GPR40 agonist, was presented at the 71st Scientific Sessions of the American Diabetes Association taking place from 24 – 28 June 2011 at San Diego, California.
CNX-011-67 is a novel small molecule candidate that, by acting on the pancreatic beta cells, will enhance glucose sensitivity, insulin secretion and reduce metabolic stress.
The data presented in the meeting adds to the growing understanding of the critical role played by GPR40 for the health and function of the pancreatic beta cell. The two-pronged impact of GPR40 activation by CNX-011-67 simultaneously enhances insulin content and glucose-stimulated insulin secretion, while significantly reducing metabolic stress in the beta cell and consequent apoptosis.
CNX-011-67 is being developed by Connexios as an oral anti-diabetic that can potentially be positioned as a key early therapy for diabetics, protecting against beta cell decline and delaying the onset or progression of disease, while providing robust glycemic control.